Klaria Pharma (KLAR) Q2 2026 earnings summary

Executive summary

• Focus during Q2 2026 was on strengthening financial position and preparing for the launch of Sumatriptan Alginate Film in Europe, with ongoing business development and strategic review.

• Bridge financing of 25 MSEK was secured to support liquidity, and a preferential rights issue is planned to further strengthen the balance sheet.

• Preparations for the European launch of Sumatriptan Alginate Film are progressing, with milestones expected in cost reimbursement and market entry.

Financial highlights

• Net sales for Q2 2026 were 0 TSEK (0 TSEK in Q2 2025); for H1 2026, net sales were 100 TSEK (8,985 TSEK in H1 2025).

• R&D expenses for Q2 2026 were 4,414 TSEK (7,090 TSEK in Q2 2025); for H1 2026, 9,328 TSEK (10,515 TSEK in H1 2025).

• Profit after tax for Q2 2026 was -12,887 TSEK (-20,118 TSEK in Q2 2025); for H1 2026, -21,542 TSEK (-21,710 TSEK in H1 2025).

• Cash flow from operating activities for Q2 2026 was -14,792 TSEK (-2,319 TSEK in Q2 2025); for H1 2026, -14,874 TSEK (-1,718 TSEK in H1 2025).

• Cash and cash equivalents at June 30, 2026 were 8,468 TSEK (1,969 TSEK at June 30, 2025).

Outlook and guidance

• Launch of Sumatriptan Alginate Film in Europe is imminent, with expectations of stable royalty cash flows and milestone payments upon achieving reimbursement in new markets.

• Targeting 10–30% market share of the European Sumatriptan market, valued at approximately 1 billion SEK annually with double-digit growth.

• Business development efforts are ongoing for additional licensing agreements outside Europe, including the US.